Clinical trials
Cholangitis clinical trials
Below are recruiting cholangitis clinical trials, each written for real people, not researchers. We’re tracking 60 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06723275Recruiting
A study on liver transplant for different liver diseases
This trial is testing a new way to see how well patients do after a liver transplant. It includes people with severe cirrhosis, other end-stage liver diseases, or liver cancer.
Ghent, BelgiumAges 18–70 - NCT06675604Recruiting
Liver transplant data collection study
This study collects data from adults listed for liver transplants due to severe liver disease or liver cancer. It aims to improve transplant care by learning from real-world patient information.
ViennaAges 18–70 - NCT03146910Recruiting
Study of primary biliary cholangitis in Switzerland
This study follows adults with primary biliary cholangitis (a long-term liver and bile duct condition). It may help doctors better understand the disease in different people, including those identified by specific blood antibody tests.
Lugano, Canton TicinoAges 18 years+ - NCT06591468Enrolling by invitationPhase 2/Phase 3
Prednisone Plus Ursodeoxycholic Acid for PBC Patients
This trial tests adding prednisone (a steroid) to ursodeoxycholic acid (a bile acid medicine) for people with primary biliary cholangitis who have a specific type of liver inflammation. The goal is to see if the combination works better at controlling the disease than standard care.
Guangzhou, GuangdongAges 18–75 - NCT06286709RecruitingPhase 2
Fecal transplant for PSC and colitis
This trial tests whether a fecal (stool) transplant from a healthy donor can help people with both PSC and inflammatory bowel disease. It aims to see if the treatment can improve liver health and reduce inflammation. You must have early to moderate liver scarring and be on stable medications.
BirminghamAges 18 years+ - NCT06051617RecruitingPhase 3
Seladelpar for liver scarring in primary biliary cholangitis
This trial tests a medicine called seladelpar for people with primary biliary cholangitis (PBC) and cirrhosis, a form of liver scarring. The goal is to see if it can help improve liver health and reduce symptoms.
Birmingham, AlabamaAges 18 years+ - NCT06016842RecruitingPhase 3
Long-term study of elafibranor for primary biliary cholangitis
This trial tests a drug called elafibranor for people with primary biliary cholangitis (PBC), a liver disease. It aims to see if the drug is safe and works well over a long time.
Tucson, ArizonaAges 18 years+ - NCT05925309Recruiting
Oral antibiotics to prevent bile duct inflammation after Kasai surgery
This trial studies whether giving oral antibiotics before symptoms start can lower the chance of cholangitis (bile duct infection/inflammation) after Kasai portoenterostomy. It may help protect your child’s bile flow and reduce painful or serious infections after surgery.
Shanghai, Shanghai MunicipalityAges 2 weeks–3 months - NCT05912387RecruitingEarly Phase 1
Testing statin treatment in primary sclerosing cholangitis
This early study looks at how a statin (cholesterol-lowering medicine) affects people with primary sclerosing cholangitis (PSC) by measuring changes using multiple types of health data. It may help researchers understand which people benefit and how PSC biology changes with treatment.
Stanford, CaliforniaAges 18–80 - NCT05749822RecruitingPhase 2/Phase 3
Fenofibrate for primary biliary cholangitis with stable cirrhosis
This trial studies whether fenofibrate (a cholesterol medicine) can improve outcomes in people with primary biliary cholangitis (PBC) who already take ursodeoxycholic acid (UDCA) but still have abnormal liver blood tests. It specifically looks at people with “compensated” (stable) cirrhosis—meaning the liver disease is present but not causing severe complications right now.
Beijing, Beijing MunicipalityAges 18–75 - NCT05751967RecruitingPhase 3
Fenofibrate plus ursodeoxycholic acid for primary biliary cholangitis
This trial tests whether adding fenofibrate to ursodeoxycholic acid (UDCA) can improve liver test results in people with primary biliary cholangitis (PBC) who did not respond enough to UDCA alone. It aims to see if the combination works better and is safe for adults with persistent, abnormal liver markers.
Lanzhou, GansuAges 18–75 - NCT04685200Recruiting
Study causes of primary sclerosing cholangitis using body scans
This study looks at what drives primary sclerosing cholangitis (PSC) and how it affects the body, using a team approach and medical tests like scans and blood work. It may help researchers understand PSC better and could improve future treatment decisions.
Bethesda, MarylandAges 18–90 - NCT05061680Recruiting
Balloon treatment for large bile duct stones
This trial looks at a procedure that uses a large balloon to help remove big stones from the bile duct. It may help people with large common bile duct stones who are safe for this approach.
HelsinkiAges 18–95 - NCT05187312Recruiting
Registry for advanced endoscopy procedures
This study is a registry that collects information about people who need an endoscopy procedure. It may help doctors learn which approaches work best and improve care over time.
StockholmAges 18 years+ - NCT07640243Recruiting
Sedation Methods for Bile Duct Drainage Procedures
This study compares different sedation (sleep) methods used during a procedure to drain blocked bile ducts. Researchers want to see which sedation approach gives patients the best experience and fastest recovery.
Ankara, AnkaraAges 18 years+ - NCT07598669Recruiting
Austrian Primary Biliary Cholangitis Registry Study
This is a registry study that collects health information from people with primary biliary cholangitis (PBC), a rare liver disease where the immune system damages bile ducts. By joining, you help researchers better understand PBC and improve care for patients with this condition.
Klagenfurt, CarinthiaAges 18 years+ - NCT07424677RecruitingPhase 3
Saroglitazar for PBC with incomplete UDCA response
This trial tests a new oral medication, saroglitazar magnesium, for people with Primary Biliary Cholangitis (PBC) who have not improved enough on standard therapy (UDCA) or cannot tolerate it. The goal is to see if it can help control liver enzymes and improve outcomes.
Lakewood Rch, FloridaAges 18–80 - NCT06864195Recruiting
Breath test for liver cancer detection
This study tests a simple breath test to detect liver cancer and monitor liver health. It is looking for patients with liver cancer, liver cirrhosis, primary sclerosing cholangitis, or people with normal livers to see if the breath test can help tell the difference.
LondonAges 18 years+ - NCT07296458RecruitingPhase 3
Fenofibrate for first-line treatment of primary biliary cholangitis
This study tests whether fenofibrate, a medicine that lowers fats in the blood, can help people with primary biliary cholangitis (a chronic liver disease) who haven't had treatment before. It aims to see if it is safe and effective as a first treatment option.
Xi'an, ShaanxiAges 18–75 - NCT07282353RecruitingPhase 3
Study of CS0159 for primary biliary cholangitis with poor UDCA response
This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.
Hefei, AnhuiAges 18–75 - NCT04650243RecruitingPhase 4
Testing whether lowering UDCA helps people with PBC
This trial looks at whether slowly reducing UDCA (a medication for primary biliary cholangitis) is safe and still helpful in people whose liver tests have improved. It may help some patients avoid higher doses if their disease is well controlled.
BeijingAges 18 years+ - NCT04037007Recruiting
Fistulotomy during ERCP to open the bile duct entrance
This trial looks at whether a specific small procedure during ERCP helps doctors reach and drain the bile duct when gallstones or bile duct narrowing are suspected. It may help people avoid getting stuck during the procedure and improve how successfully the bile duct can be reached.
Mexico City, Mexico CityAges 18–90 - NCT07149675Recruiting
Long-term study for primary biliary cholangitis patients
This study tracks patients with primary biliary cholangitis (PBC) over time to understand long-term outcomes. It aims to gather information that could improve care and management for people with PBC.
Beijing, Select A State Or ProvinceAges Any age - NCT06865924Recruiting
Understanding genetic causes in atypical PSC using liver cells
This study creates mini-livers (colangioids) from tiny tissue samples to find genetic reasons for atypical primary sclerosing cholangitis (aPSC), a rare liver disease. It aims to help doctors better understand and diagnose the condition.
Milan, MIAges 18–90
Hear when a new Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cholangitis?
- Yes. Clin2 currently lists 60 recruiting cholangitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cholangitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cholangitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.